CRBP Corbus Pharmaceuticals Holdings, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1595097 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-72.3%
TTM EPS YoY-10.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-131.5%
ROA-100.1%
ROIC (approx.)-160.1%
Asset turnover—
Leverage & solvency
Liabilities / assets31.0%
Debt / equity0.00x
Current ratio3.40x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.79x
Accruals ratio-20.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $34.25M | $31.18M | $19.82M | $18.41M | $20.86M | $15.19M | $15.64M | $8.79M |
| SG&A expense | $4.58M | $5.01M | $4.49M | $3.56M | $3.56M | $3.96M | $4.13M | $3.82M |
| Operating income | -$38.82M | -$36.19M | -$24.30M | -$21.97M | -$24.42M | -$19.15M | -$19.77M | -$12.61M |
| Interest expense | — | — | — | $0 | $0 | $0 | $0 | $0 |
| Net income | -$37.75M | -$35.04M | -$22.97M | -$20.55M | -$23.34M | -$17.66M | -$16.98M | -$9.53M |
| EBITDA | -$38.72M | -$36.14M | -$24.25M | -$21.92M | -$24.32M | -$19.05M | -$19.69M | -$12.47M |
| EPS (basic) | -1.81 | -1.81 | -1.23 | — | -1.90 | -1.44 | -1.39 | — |
| EPS (diluted) | -1.81 | -1.81 | -1.23 | — | -1.90 | -1.44 | -1.39 | — |
| Weighted avg. shares (diluted) | 20.84M | 19.41M | 18.71M | — | 12.31M | 12.24M | 12.20M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $30.25M | $23.37M | $25.66M | $28.49M | $26.98M | $20.04M | $18.90M | $17.20M |
| Short-term investments | $85.09M | $94.57M | $112.56M | $134.78M | $77.00M | $96.55M | $113.89M | $131.86M |
| Current assets | $118.95M | $122.75M | $143.57M | $166.95M | $107.57M | $122.83M | $137.36M | $152.98M |
| PP&E, net | $36,000 | $71,000 | $116,000 | $159,000 | $201,000 | $251,000 | $304,000 | $385,000 |
| Total assets | $122.90M | $126.99M | $144.48M | $168.19M | $109.51M | $125.08M | $139.93M | $155.88M |
| Current liabilities | $34.97M | $21.48M | $18.14M | $20.69M | $17.06M | $13.33M | $11.62M | $11.82M |
| Total liabilities | $38.14M | $24.75M | $18.14M | $20.69M | $17.37M | $14.09M | $12.82M | $13.45M |
| Shareholders' equity | $84.76M | $102.24M | $126.34M | $147.50M | $92.15M | $110.99M | $127.11M | $142.43M |
| Shares outstanding | 20.61M | 18.67M | 17.74M | 17.61M | 12.53M | 12.25M | 12.23M | 12.18M |
| Cash flow statement | ||||||||
| Operating cash flow | -$21.24M | -$29.63M | -$25.57M | -$15.92M | -$15.55M | -$16.60M | -$16.42M | -$10.94M |
| Capital expenditure | $15,000 | $6,000 | $6,000 | $7,000 | $0 | $0 | $0 | — |
| Free cash flow | -$21.25M | -$29.63M | -$25.58M | -$15.93M | -$15.55M | -$16.60M | -$16.42M | — |
| Investing cash flow | $9.56M | $18.26M | $22.45M | -$57.15M | $19.64M | $17.74M | $18.12M | $8.73M |
| Financing cash flow | $18.55M | — | — | $74.58M | $2.85M | $0 | $0 | -$13,000 |
| Depreciation & amortization | $100,000 | $50,000 | $49,000 | $49,000 | $100,000 | $100,000 | $81,000 | $134,000 |
| Stock-based compensation | $1.81M | $1.81M | $1.92M | $1.43M | $1.58M | $1.56M | $1.71M | $1.63M |
Free plan shows the latest 8 periods; Pro shows all 53 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.